本文已被：浏览 822次 下载 551次
投稿时间：2019-09-11 网络发布日期：2020-06-20
投稿时间：2019-09-11 网络发布日期：2020-06-20
中文摘要: 目的 探究多发性骨髓瘤(MM)患者血清中长链非编码RNA(lncRNA) FOXD3-AS1的表达,分析其与临床病理特征及预后的关系。方法 以2014年1月至2018年4月在秦皇岛市工人医院进行治疗的82例MM患者作为研究对象,另选取70例健康者作为对照组,采集外周血,采用实时荧光定量PCR(qRT-PCR)法检测所有受试者外周血中lncRNA FOXD3-AS1表达,受试者工作特征曲线分析lncRNA FOXD3-AS1在MM中的诊断价值;分析其与MM患者临床参数及治疗效果的关系,采用COX回归分析MM患者预后危险因素。结果 与对照组相比,MM患者lncRNA FOXD3-AS1表达水平升高(P<0.05)。lncRNA FOXD3-AS1表达与临床分期、骨病分级有关(P<0.05)。ROC分析显示,lncRNA FOXD3-AS1对MM预测的AUC值为0.837(95%CI:0.816~0.851),最佳截断值为1.27。lncRNA FOXD3-AS1高表达组临床治疗有效率显著低于lncRNA FOXD3-AS1低表达组(P<0.05)。随访1年,25例死亡,死亡率为30.48%,COX多因素分析显示,临床分期、骨病分级、lncRNA FOXD3-AS1表达为影响MM患者预后的独立因素。 lncRNA FOXD3-AS1高表达组死亡率显著高于低表达组［38.78%（19/49） vs18.18%(6/33),χ2=3.946,P=0.047］。结论 MM患者血清中lncRNA FOXD3-AS1表达上调,是影响患者生存的独立危险因素。
Abstract:Objecitve To investigate the expression of long non-coding RNA (lncRNA) FOXD3-AS1 in serum of patients with multiple myeloma (MM) to analyze its relationship with clinicopathological features and prognosis. Methods Eighty-two patients with MM were selected as the research group, and 70 healthy persons were served as the control group at the same time.The real-time fluorescence quantitative PCR (qRT-PCR) was used to detect the expression of lncRNA FOXD3-AS1 in peripheral blood of all subjects.Receiver operating characteristics (ROC) curve was used to analyze the value of lncRNA FOXD3-AS1 in the diagnosis of multiple myeloma and its relationships with clinical parameters and therapeutic effect of MM patients.COX regression was used to analyze the prognostic risk factors MM patients. Results Compared with control group, the expression level of lncRNA FOXD3-AS1 in MM patients statistically increased (P<0.05) and was related to clinical stage and grade of osteopathy (P<0.05). ROC analysis showed that the predicted AUC value of lncRNA FOXD3-AS1 for MM was 0.837 (95%CI :0.816-0.851) with an optimal cut-off value of 1.27. The clinical efficacy in patients with high expression of lncRNA FOXD3-AS1 was significantly lower than that of patients with low expression of lncRNA FOXD3-AS1 (P<0.05).During one year of follow-up, 25 patients died with a mortality rate of 30.48%. Multivariate COX analysis showed that clinical stage, grade of osteopathy and expression of lncRNA FOXD3-AS1 were the independent factors influencing the prognosis of MM patients.The mortality rate in patients with high expression of lncRNA FOXD3-AS1 was significantly higher than that of patients with low expression (38.78% vs 18.18%, χ2=3.946, P=0.047). Conclusion High expression of lnc RNA FOXD3-AS1 is an independent risk factor for survival in MM patients.
文章编号： 中图分类号： 文献标志码：A
基金项目:河北省医学科学研究重点课题计划项目(20161723)
附件
| 作者 | 单位 |
| 王涛1 | 1.秦皇岛市工人医院检验科,河北 秦皇岛 066200 |
| 秦涛2 | 2.秦皇岛市工人医院放射科,河北 秦皇岛 066200 |
| 李玉凤1 | 1.秦皇岛市工人医院检验科,河北 秦皇岛 066200 |
| Author Name | Affiliation |
| WANG Tao*, QIN Tao, LI Yu-feng | *Department of Clinical Laboratory, Qinhuangdao Workers Hospital, Qinhuangdao, Hebei 066200, China |
引用文本：
王涛,秦涛,李玉凤.lncRNA FOXD3-AS1在多发性骨髓瘤中的表达及临床意义[J].中国临床研究,2020,33(6):733-736,742.
王涛,秦涛,李玉凤.lncRNA FOXD3-AS1在多发性骨髓瘤中的表达及临床意义[J].中国临床研究,2020,33(6):733-736,742.